Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma
- 22 October 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 106 (17) , 2224-2230
Abstract
Background— Recent studies have demonstrated that lesions of aortic sclerosis and stenosis share several similarities with lesions of atherosclerosis. In atherosclerosis, angiotensin-converting enzyme (ACE) is expressed by a subset of macrophages. This study was undertaken to determine whether ACE might be present in aortic sclerosis or stenosis lesions. Methods and Results— Immunohistochemistry was performed on 26 paraffin-embedded human aortic valves. Monospecific antibodies were used to identify ACE, macrophages, angiotensin II type 1 receptor (AT-1 receptor), angiotensin II, and apolipoprotein B. Human low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were isolated from plasma of normal volunteers by sequential density-gradient ultracentrifugation. ACE was not present in normal valves but was present in all valves with aortic sclerosis or stenosis lesions. ACE was detected on a subset of lesion macrophages but was present primarily in an extracellular distribution, where it colocalized with apolipoprotein B. ACE was detected by Western blotting on plasma LDL but not on HDL isolated from normal volunteers. Angiotensin II, the enzymatic product of ACE, was colocalized with ACE in valve lesions. ACE also was colocalized with apolipoprotein B in an adjacent coronary atherosclerotic plaque. Conclusions— ACE is present in aortic sclerosis and stenosis lesions, where it may participate in lesion development, as is evidenced by the presence of its enzymatic product, angiotensin II. The observation of an association of ACE with LDL in both lesions and plasma suggests that LDL may deliver ACE to lesions and has implications for the role of ACE-containing LDL in other diseases, such as atherosclerosis.Keywords
This publication has 10 references indexed in Scilit:
- HMG CoA reductase inhibitor (statin) and aortic valve calciumThe Lancet, 2002
- Angiotensin II Reduces Macrophage Cholesterol Efflux: A Role for the AT-1 Receptor but Not for the ABC1 TransporterBiochemical and Biophysical Research Communications, 2002
- Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older personsThe American Journal of Cardiology, 2001
- Are atherosclerotic processes involved in aortic-valve calcification?The Lancet, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Clinical Factors Associated With Calcific Aortic Valve DiseaseJACC, 1997
- Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.Journal of Clinical Investigation, 1995
- Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosisJACC, 1994
- Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valvesJACC, 1994
- Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells.Journal of Clinical Investigation, 1986